FimmCyte has announced strategic research collaboration
FimmCyte has announced a strategic research collaboration with pharmaceutical company Gedeon Richter Plc. to advance a potential new treatment for endometriosis.
The partnership focuses on FimmCyte’s lead candidate FMC2, a first-in-class immunotherapy designed to target the underlying causes of the disease rather than only managing symptoms.
Endometriosis affects around one in ten women worldwide and can lead to chronic pain, fertility challenges, and reduced quality of life. Under the agreement, the two companies will jointly conduct research and development activities to move FMC2 toward clinical testing. Gedeon Richter will hold an exclusive global option to license the therapy before the start of the first-in-human clinical trial.
FimmCyte was founded in 2022 as a spin-off from the University of Zurich and University Hospital Zurich and focuses on targeted immunotherapies for chronic fibro-inflammatory diseases. The collaboration aims to combine FimmCyte’s scientific platform with Richter’s expertise in women’s health to accelerate the development of new treatment options for patients.
Co-founder and CSO Valentina Vongrad was awarded an Entrepreneur Fellowship in 2022.
